{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:28:38Z","timestamp":1792319318261,"version":"4.4.0"},"reference-count":117,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Non-small cell lung cancer (NSCLC) patients are often complicated by other respiratory diseases, including interstitial pneumonia (IP), chronic obstructive pulmonary disease (COPD), and pulmonary tuberculosis (TB), and the management of which can be problematic. NSCLC patients with IP sometimes develop fatal acute exacerbation induced by pharmacotherapy, and the establishment of a safe treatment strategy is desirable. For advanced NSCLC with IP, carboplatin plus nanoparticle albumin-bound paclitaxel is a relatively safe and effective first-line treatment option. Although the safety of immune checkpoint inhibitors (ICIs) for these populations remains controversial, ICIs have the potential to provide long-term survival. The severity of COPD is an important prognostic factor in NSCLC patients. Although COPD complications do not necessarily limit treatment options, it is important to select drugs with fewer side effects on the heart and blood vessels as well as the lungs. Active TB is complicated by 2\u20135% of NSCLC cases during their disease course. Since pharmacotherapy, especially ICIs, reportedly induces the development of TB, the possibility of developing TB should always be kept in mind during NSCLC treatment. To date, there is no coherent review article on NSCLC with these pulmonary complications. This review article summarizes the current evidence and discusses future prospects for treatment strategies for NSCLC patients complicated with IP, severe COPD, and TB.<\/jats:p>","DOI":"10.3390\/cancers16091734","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:13:22Z","timestamp":1714371202000},"page":"1734","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis"],"prefix":"10.3390","volume":"16","author":[{"given":"Ryota","family":"Otoshi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-7911","authenticated-orcid":false,"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Sagawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieri","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosumi","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Moriuchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimasa","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6602061","article-title":"The epidemiology of interstitial lung disease and its association with lung cancer","volume":"91","author":"Raghu","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1440-1843.2009.01547.x","article-title":"Cumulative incidence of and predictive factors for lung cancer in IPF","volume":"14","author":"Ozawa","year":"2009","journal-title":"Respirology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.athoracsur.2015.03.094","article-title":"Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia","volume":"100","author":"Omori","year":"2015","journal-title":"Ann. Thorac. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.21037\/jtd.2019.10.01","article-title":"Real world data of combined lung cancer and interstitial lung disease","volume":"11","author":"Kawahara","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","article-title":"Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy","volume":"134","author":"Selman","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.5858\/arpa.2011-0511-OA","article-title":"Idiopathic Pulmonary Fibrosis May Be a Disease of Recurrent, Tractional Injury to the Periphery of the Aging Lung: A Unifying Hypothesis Regarding Etiology and Pathogenesis","volume":"136","author":"Leslie","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1582-4934.2002.tb00188.x","article-title":"MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis","volume":"6","author":"Demopoulos","year":"2002","journal-title":"J. Cell. Mol. Med."},{"key":"ref_8","first-page":"8527","article-title":"Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis","volume":"61","author":"Uematsu","year":"2001","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","article-title":"Epidemi-ologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences","volume":"190","author":"Natsuizaka","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1378\/chest.14-0359","article-title":"The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis","volume":"147","author":"Tomassetti","year":"2015","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00408-014-9664-8","article-title":"Radiological Characteristics, Histological Features and Clinical Outcomes of Lung Cancer Patients with Coexistent Idiopathic Pulmonary Fibrosis","volume":"193","author":"Khan","year":"2014","journal-title":"Lung"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: Incidence, risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1378\/chest.07-0323","article-title":"Acute Exacerbation of Interstitial Pneumonia Other Than Idiopathic Pulmonary Fibrosis","volume":"132","author":"Park","year":"2007","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2010.04.014","article-title":"The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias","volume":"71","author":"Minegishi","year":"2011","journal-title":"Lung Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000342046","article-title":"Efficacy of Chemotherapy for Advanced Non-Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis","volume":"85","author":"Watanabe","year":"2012","journal-title":"Respiration"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13014-017-0881-1","article-title":"Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: A retrospective analysis","volume":"12","author":"Nakajima","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rana, J.N., Mumtaz, S., Han, I., and Choi, E.H. (2024). Formation of reactive species via high power microwave induced DNA damage and promoted intrinsic pathway-mediated apoptosis in lung cancer cells: An in vitro investigation. Fundam. Res., in\u00a0press.","DOI":"10.1016\/j.fmre.2024.02.001"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-5231(03)00122-9","article-title":"Mechanisms in pulmonary toxicology","volume":"25","author":"Delaunois","year":"2004","journal-title":"Clin. Chest Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/JTO.0b013e318216ee6b","article-title":"The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer","volume":"6","author":"Kenmotsu","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2016.03.017","article-title":"Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer","volume":"96","author":"Enomoto","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1378\/chest.15-0530","article-title":"Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline","volume":"149","author":"Salisbury","year":"2016","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/resp.13075","article-title":"Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer","volume":"22","author":"Kobayashi","year":"2017","journal-title":"Respirology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.resinv.2019.06.001","article-title":"Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia","volume":"57","author":"Ogura","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/1759-7714.13736","article-title":"Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"12","author":"Isono","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2021.03.014","article-title":"Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease","volume":"155","author":"Tasaka","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","article-title":"Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody","volume":"69","author":"Shibaki","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.21037\/tlcr-22-162","article-title":"Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: A systematic review and meta-analysis of cohort studies","volume":"11","author":"Matsumoto","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.chest.2021.12.656","article-title":"Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Me-ta-analysis","volume":"161","author":"Zhang","year":"2022","journal-title":"Chest"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.lungcan.2019.06.001","article-title":"Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial","volume":"134","author":"Fujimoto","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","article-title":"A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis","volume":"15","author":"Ikeda","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for inter-stitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lungcan.2013.01.017","article-title":"Preex-isting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma","volume":"80","author":"Fujimoto","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00301","article-title":"Deleterious Pul-monary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia","volume":"2","author":"Honda","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fujimoto, K., Ikeda, S., Tabata, E., Kaneko, T., Sagawa, S., Yamada, C., Kumagai, K., Fukushima, T., Haga, S., and Watanabe, M. (2024). KRAS G12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid In-terstitial Pneumonia. Cancers, 16.","DOI":"10.3390\/cancers16071327"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1111\/cas.14217","article-title":"Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease","volume":"110","author":"Kenmotsu","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2019.09.020","article-title":"A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)","volume":"138","author":"Asahina","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10147-019-01516-9","article-title":"Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: A single-arm phase II study","volume":"24","author":"Fukuizumi","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00280-016-3040-8","article-title":"Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: A pilot study","volume":"77","author":"Sekine","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2018.09.007","article-title":"A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease","volume":"125","author":"Hanibuchi","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.resinv.2023.06.002","article-title":"Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study","volume":"61","author":"Omori","year":"2023","journal-title":"Respir. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2200380","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: A randomised phase 3 trial","volume":"60","author":"Otsubo","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hamada, S., Ichiyasu, H., Ikeda, T., Inaba, M., Kashiwabara, K., Sadamatsu, T., Sato, N., Akaike, K., Okabayashi, H., and Saruwatari, K. (2019). Protective effect of bevacizumab on chemothera-py-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer. BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-0838-2"},{"key":"ref_48","first-page":"4259","article-title":"Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study","volume":"35","author":"Enomoto","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00280-014-2590-x","article-title":"The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease","volume":"74","author":"Shimizu","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"00184-2019","DOI":"10.1183\/23120541.00184-2019","article-title":"Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: Nationwide surveillance in Japan","volume":"6","author":"Minegishi","year":"2020","journal-title":"ERJ Open Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00280-015-2775-y","article-title":"Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia","volume":"76","author":"Watanabe","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00280-014-2670-y","article-title":"Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease","volume":"75","author":"Kenmotsu","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kato, M., Shukuya, T., Takahashi, F., Mori, K., Suina, K., Asao, T., Kanemaru, R., Honma, Y., Muraki, K., and Sugano, K. (2014). Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-508"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS\u00ae trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12931-016-0398-4","article-title":"A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)","volume":"17","author":"Iwata","year":"2016","journal-title":"Respir. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1183\/09031936.00144208","article-title":"COPD prevalence is increased in lung cancer, independent of age, sex and smoking history","volume":"34","author":"Young","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2147\/COPD.S68766","article-title":"Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and\/or tyrosine kinase inhibitors","volume":"9","author":"Izquierdo","year":"2014","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/resp.12661","article-title":"Impact of COPD and emphysema on survival of patients with lung cancer: A meta-analysis of observational studies","volume":"21","author":"Gao","year":"2015","journal-title":"Respirology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00408-014-9675-5","article-title":"The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients","volume":"193","author":"Iachina","year":"2014","journal-title":"Lung"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15412555.2013.838946","article-title":"Chronic Obstructive Pulmonary Disease in Stage I Non-small Cell Lung Cancer That Underwent Anatomic Resection: The Role of a Recurrence Promoter","volume":"11","author":"Kuo","year":"2014","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4104\/pcrj.2009.00048","article-title":"Recent trends in lung cancer and its association with COPD: An analysis using the UK GP Research Database","volume":"19","author":"Soriano","year":"2009","journal-title":"Prim. Care Respir. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.2147\/COPD.S168048","article-title":"Impact of COPD on prognosis of lung cancer: From a perspective on disease heterogeneity","volume":"13","author":"Wang","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.2147\/COPD.S149456","article-title":"Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy","volume":"12","author":"Omote","year":"2017","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.2147\/COPD.S182173","article-title":"Impact of chemotherapy in the prognosis of non-small-cell lung cancer patients with severe to very severe COPD","volume":"13","author":"Dong","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_66","first-page":"116","article-title":"Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy","volume":"8","author":"Hayama","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Goffin, J.R., Corriveau, S., Tang, G.H., and Pond, G.R. (2021). Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251886"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/thx.2009.128082","article-title":"Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: A comprehensive analysis using data from primary care","volume":"65","author":"Feary","year":"2010","journal-title":"Thorax"},{"key":"ref_69","first-page":"1103","article-title":"Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer","volume":"32","author":"Tamiya","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s12253-019-00661-w","article-title":"Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer","volume":"26","author":"Szentkereszty","year":"2019","journal-title":"Pathol. Oncol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.21037\/tlcr-21-214","article-title":"Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors","volume":"10","author":"Zhou","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/ijc.32235","article-title":"Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease","volume":"145","author":"Shin","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1164\/rccm.201704-0795OC","article-title":"Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non\u2013Small Cell Lung Cancer","volume":"197","author":"Mark","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1164\/rccm.201504-0782OC","article-title":"Dysreg-ulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis","volume":"193","author":"McKendry","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.21037\/tlcr-22-667","article-title":"Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: A retrospective cohort study","volume":"11","author":"Zhang","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ikeda, S., Kato, T., Kenmotsu, H., Sekine, A., Baba, T., and Ogura, T. (2021). Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia. Cancers, 13.","DOI":"10.3390\/cancers13163979"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"23677","DOI":"10.1038\/s41598-021-03139-5","article-title":"Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer","volume":"11","author":"Ajimizu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.25616","article-title":"Pulmonary tuberculosis increases the risk of lung cancer: A population-based cohort study","volume":"117","author":"Wu","year":"2011","journal-title":"Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/ijc.30384","article-title":"Tuberculosis, smoking and risk for lung cancer incidence and mortality","volume":"139","author":"Hong","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/cid\/ciw838","article-title":"Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis","volume":"64","author":"Cheng","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.resinv.2015.11.001","article-title":"Cumulative incidence of tuberculosis in lung cancer patients in Japan: A 6-year observational study","volume":"54","author":"Suzuki","year":"2016","journal-title":"Respir. Investig."},{"key":"ref_84","first-page":"49","article-title":"A study of coexistence of bronchogenic carcinoma and active pulmonary tuberculosis (author\u2019s transl)","volume":"56","author":"Komatsu","year":"1981","journal-title":"Kekkaku"},{"key":"ref_85","first-page":"901","article-title":"A study on active pulmonary tuberculosis with coexistent lung carcinoma","volume":"49","author":"Ogawa","year":"1990","journal-title":"Nihon Kyobu Rinsho"},{"key":"ref_86","first-page":"119","article-title":"A clinical study on coexistence of active pulmonary tuberculosis and lung cancer","volume":"67","author":"Kurasawa","year":"1992","journal-title":"Kekkaku"},{"key":"ref_87","first-page":"157","article-title":"Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. Clinical study on pulmonary tuberculosis associated with lung cancer patients","volume":"74","author":"Watanabe","year":"1999","journal-title":"Kekkaku"},{"key":"ref_88","first-page":"382","article-title":"Coexisting lung cancer and active pulmonary mycobacteriosis","volume":"45","author":"Tamura","year":"2007","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.5588\/ijtld.14.0161","article-title":"Tuberculosis and risk of cancer: A Danish nationwide cohort study","volume":"18","author":"Simonsen","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4049\/jimmunol.181.1.116","article-title":"Programmed Death (PD)-1:PD-Ligand 1\/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis","volume":"181","author":"Jurado","year":"2008","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e1S","DOI":"10.1378\/chest.12-2345","article-title":"Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Alberg","year":"2013","journal-title":"Chest"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1378\/chest.128.4.2218","article-title":"Clinical Characteristics and Treatment Responses of Tuberculosis in Patients with Malignancy Receiving Anticancer Chemotherapy","volume":"128","author":"Kim","year":"2005","journal-title":"Chest"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10120-011-0037-1","article-title":"Increased risk of tuberculosis after gastrectomy and chemotherapy in gastric cancer: A 7-year cohort study","volume":"14","author":"Huang","year":"2011","journal-title":"Gastric Cancer"},{"key":"ref_94","first-page":"17","article-title":"Tuberculosis and Lung Cancer","volume":"91","author":"Tamura","year":"2016","journal-title":"Kekkaku"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"eaat2702","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer im-munotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jiac.2018.06.016","article-title":"Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents","volume":"25","author":"Takata","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e52668","DOI":"10.7554\/eLife.52668","article-title":"Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1","volume":"9","author":"Tezera","year":"2020","journal-title":"eLife"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"ofaa126","DOI":"10.1093\/ofid\/ofaa126","article-title":"Incidence of Active Tu-berculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/thoraxjnl-2021-217575","article-title":"Pulmonary tuberculosis associated with immune checkpoint inhibitors: A pharmacovigilance study","volume":"77","author":"Zhu","year":"2022","journal-title":"Thorax"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5588\/ijtld.12.0816","article-title":"Tuberculosis is associated with increased lung cancer mortality","volume":"17","author":"Leung","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S3392","DOI":"10.21037\/jtd.2018.07.11","article-title":"Identifying lung cancer in patients with active pulmonary tuberculosis","volume":"10","author":"Parker","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Hirashima, T., Tamura, Y., Han, Y., Hashimoto, S., Tanaka, A., Shiroyama, T., Morishita, N., Suzuki, H., Okamoto, N., and Akada, S. (2018). Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: A retrospective study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4889-1"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2018.05.030","article-title":"Management of co-existent tuberculosis and lung cancer","volume":"122","author":"Ho","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e13432","DOI":"10.1111\/eci.13432","article-title":"Associated factors of co-existent pulmonary tu-berculosis and lung cancer: A case-control study","volume":"51","author":"Zheng","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1017\/S0950268822000176","article-title":"Comparison of clinical and imaging features between pulmonary tuberculosis complicated with lung cancer and simple pulmonary tuberculosis: A systematic review and meta-analysis","volume":"150","author":"Sun","year":"2022","journal-title":"Epidemiol. Infect."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1700157","DOI":"10.1183\/13993003.00157-2017","article-title":"Risk of tuberculosis in patients with solid cancers and haematological ma-lignancies: A systematic review and meta-analysis","volume":"50","author":"Dobler","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","volume":"27","author":"Champiat","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jiac.2021.10.017","article-title":"Tuberculosis during lung cancer treatment-A case series","volume":"28","author":"Tamura","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_110","first-page":"1021","article-title":"Waning of the specific interferon-gamma response after years of tuberculosis infection","volume":"11","author":"Mori","year":"2007","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jiac.2019.10.018","article-title":"Recent trends in the incidence of latent tuberculosis infection in Japanese patients with lung cancer: A small retrospective study","volume":"26","author":"Tamura","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.21037\/atm-20-5964","article-title":"Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis","volume":"8","author":"Ye","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jiac.2013.11.005","article-title":"Mycobacterium tuberculosis infection in cancer patients at a tertiary care cancer center in Japan","volume":"20","author":"Fujita","year":"2014","journal-title":"J. Infect. Chemother."},{"key":"ref_114","first-page":"13","article-title":"Cancer and Tuberculosis\/Nontuberculous Mycobacteriosis","volume":"97","author":"Tamura","year":"2022","journal-title":"Kekkaku"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1742-7843.2005.pto_157.x","article-title":"Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin","volume":"97","author":"Kajosaari","year":"2005","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","article-title":"The effects of CYP3A4 inhi-bition on erlotinib pharmacokinetics: Computer-based simulation (SimCYP) predicts in vivo metabolic inhibition","volume":"64","author":"Rakhit","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_117","unstructured":"Bragalone, D.L. (2013). Drug Information Handbook for Oncology, Lexi-Comp. [11th ed.]."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1734\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:35:57Z","timestamp":1760106957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":117,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cancers16091734"],"URL":"https:\/\/doi.org\/10.3390\/cancers16091734","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}